Canntab Therapeutics; two MMJ DEVELOPMENTS and upd
Post# of 273249
(Total Views: 195)
Posted On: 04/30/2018 2:11:24 PM
Canntab Therapeutics; two MMJ DEVELOPMENTS and updated news.
Canntab Therapeutics Limited (CSE: PILL) (“Canntab” or the “Company”) is pleased to announce two recent developments: (i) an update on its application for a Dealer’s License with Health Canada; and (ii) its Australian joint venture partner has obtained a license to import medical cannabis products.
Application for a Dealer’s License with Health Canada.
The Company has engaged an experienced consultant for the purposes of finalizing and submitting an application to obtain a Health Canada Dealer’s License (“Dealer’s License”) under the Controlled Drugs and Substances Act (“CDSA”) and its associated regulations. The Dealer’s License will allow Canntab to continue with the development of its proprietary products including the XR Tablet and will allow Canntab to manufacture and sell the products in Canada and elsewhere.
Further, the Dealer’s License, when combined with an export permit that the Company intends to apply for after receiving its Dealer’s License, will allow the Company to export its proprietary Extended Release Tablet (“XR Tablet”) to certain international markets. Trevor Moore, a veteran of the Canadian medical cannabis industry, has been retained by the Company to assist in preparing its application for a Dealer’s License. Mr. Moore has previously helped two Licensed Producers obtain their licenses, and is an expert in the areas of quality assurance, regulatory compliance and government relations.
Australian Joint Venture
Canntab entered into a joint venture agreement with Queensland Bauxite Ltd. (“QBL”) and its wholly owned subsidiary Vitacan Pty Ltd. (“Vitacan”) (the “Joint Venture Agreement”) pursuant to the Joint Venture Agreement the parties shall manufacture, distribute and sell Canntab’s proprietary products including its XR cannabis tablets in Australia. The Joint Venture may extend to other territories in Asia. Pursuant to the Joint Venture Vitacan has agreed to contribute the
first $1,000,000 US of capital required by the Joint Venture.
“We are very excited to expand Canntab’s business to the Australian market which is a very progressive market for the development and sale of marijuana and marijuana products,” said Jeffrey Renwick, the CEO of Canntab.
Australian JV Partner Obtains Import License
The Company’s Australian joint venture partner, Queensland Bauxite Ltd. (“Queensland Bauxite”) and its subsidiary, Medical Cannabis Limited (“MCL”), recently announced that MCL entered into a binding memorandum of understanding (“MOU”) with Burleigh Heads Cannabis (“BHC”), which holds an import license issued by the Australian Office of Drug Control. Under the terms of the MOU, BHC will provide the import and storage services for MCL’s international medical cannabis products.
See QBL-board and website;
https://www.queenslandbauxite.com/
Read More: https://investorshangout.com/post/view?id=502...z5EBFsUq00
Canntab Therapeutics Limited (CSE: PILL) (“Canntab” or the “Company”) is pleased to announce two recent developments: (i) an update on its application for a Dealer’s License with Health Canada; and (ii) its Australian joint venture partner has obtained a license to import medical cannabis products.
Application for a Dealer’s License with Health Canada.
The Company has engaged an experienced consultant for the purposes of finalizing and submitting an application to obtain a Health Canada Dealer’s License (“Dealer’s License”) under the Controlled Drugs and Substances Act (“CDSA”) and its associated regulations. The Dealer’s License will allow Canntab to continue with the development of its proprietary products including the XR Tablet and will allow Canntab to manufacture and sell the products in Canada and elsewhere.
Further, the Dealer’s License, when combined with an export permit that the Company intends to apply for after receiving its Dealer’s License, will allow the Company to export its proprietary Extended Release Tablet (“XR Tablet”) to certain international markets. Trevor Moore, a veteran of the Canadian medical cannabis industry, has been retained by the Company to assist in preparing its application for a Dealer’s License. Mr. Moore has previously helped two Licensed Producers obtain their licenses, and is an expert in the areas of quality assurance, regulatory compliance and government relations.
Australian Joint Venture
Canntab entered into a joint venture agreement with Queensland Bauxite Ltd. (“QBL”) and its wholly owned subsidiary Vitacan Pty Ltd. (“Vitacan”) (the “Joint Venture Agreement”) pursuant to the Joint Venture Agreement the parties shall manufacture, distribute and sell Canntab’s proprietary products including its XR cannabis tablets in Australia. The Joint Venture may extend to other territories in Asia. Pursuant to the Joint Venture Vitacan has agreed to contribute the
first $1,000,000 US of capital required by the Joint Venture.
“We are very excited to expand Canntab’s business to the Australian market which is a very progressive market for the development and sale of marijuana and marijuana products,” said Jeffrey Renwick, the CEO of Canntab.
Australian JV Partner Obtains Import License
The Company’s Australian joint venture partner, Queensland Bauxite Ltd. (“Queensland Bauxite”) and its subsidiary, Medical Cannabis Limited (“MCL”), recently announced that MCL entered into a binding memorandum of understanding (“MOU”) with Burleigh Heads Cannabis (“BHC”), which holds an import license issued by the Australian Office of Drug Control. Under the terms of the MOU, BHC will provide the import and storage services for MCL’s international medical cannabis products.
See QBL-board and website;
https://www.queenslandbauxite.com/
Read More: https://investorshangout.com/post/view?id=502...z5EBFsUq00
(0)
(0)
Robert
Scroll down for more posts ▼